Latest Capital Strategy News

Wesfarmers Limited has announced a fully franked special dividend of AUD 0.40 per share alongside a substantial AUD 1.10 capital return, both payable on 4 December 2025, marking a significant milestone in its 2025 capital management strategy.

European Metals Holdings has advanced its Cinovec Lithium Project with a new preliminary mining permit and secured funding to complete its Definitive Feasibility Study, reinforcing its position in Europe's critical raw materials landscape.

Locate Technologies has ended its Australian ATM Facility, initiated a new NZ$10 million facility in New Zealand, and proposed a share buy-back pending shareholder approval, aligning with its Bitcoin Treasury ambitions.

Energy Technologies Limited reported a 33.4% increase in quarterly cash receipts alongside a 55% reduction in cash outflows for 1Q FY2026, signaling improved operational efficiency and liquidity management.

Desane Group Holdings has declared a special 2 cent per share dividend following the sale of a key property in Lane Cove, signalling a direct return of capital to shareholders.

Tlou Energy Limited reported a $1.07 million net cash outflow for Q3 2025 and secured $2.37 million through equity issuance, yet its funding runway remains just one quarter. The company is actively pursuing additional capital to sustain operations amid ongoing expenditure.

ENRG Elements Limited has completed a $1.6 million entitlement offer while advancing a strategic review of its portfolio, including relinquishing Canadian lithium licenses and focusing on uranium and copper assets.

Everest Metals Corporation Ltd reported a solid cash position of A$5.0 million at the end of Q3 2025, backed by a recent equity raise and ongoing exploration investments. The company’s funding runway now extends to nearly five quarters, offering a stable platform for its exploration activities.

Patronus Resources Limited reported a significant boost in cash reserves to $7.1 million for Q3 2025, driven by strong investing activity despite ongoing operating cash outflows.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Reece Limited has completed a $365 million off-market share buy-back, repurchasing 4.3% of its shares at $13 each with no scale-back applied. This move returns excess capital to shareholders while preserving financial flexibility for future growth.

Connexion Mobility Ltd has secured shareholder approval to initiate an on-market buy-back of up to 160 million shares, aiming to enhance capital management over the next year.